• Title/Summary/Keyword: Lung Cancer

Search Result 3,839, Processing Time 0.028 seconds

Calnexin as a dual-role biomarker: antibody-based diagnosis and therapeutic targeting in lung cancer

  • Soyeon Lim;Youngeun Ha;Boram Lee;Junho Shin;Taiyoun Rhim
    • BMB Reports
    • /
    • v.57 no.3
    • /
    • pp.155-160
    • /
    • 2024
  • Lung cancer carries one of the highest mortality rates among all cancers. It is often diagnosed at more advanced stages with limited treatment options compared to other malignancies. This study focuses on calnexin as a potential biomarker for diagnosis and treatment of lung cancer. Calnexin, a molecular chaperone integral to N-linked glycoprotein synthesis, has shown some associations with cancer. However, targeted therapeutic or diagnostic methods using calnexin have been proposed. Through 1D-LCMSMS, we identified calnexin as a biomarker for lung cancer and substantiated its expression in human lung cancer cell membranes using Western blotting, flow cytometry, and immunocytochemistry. Anti-calnexin antibodies exhibited complement-dependent cytotoxicity to lung cancer cell lines, resulting in a notable reduction in tumor growth in a subcutaneous xenograft model. Additionally, we verified the feasibility of labeling tumors through in vivo imaging using antibodies against calnexin. Furthermore, exosomal detection of calnexin suggested the potential utility of liquid biopsy for diagnostic purposes. In conclusion, this study establishes calnexin as a promising target for antibody-based lung cancer diagnosis and therapy, unlocking novel avenues for early detection and treatment.

Lack of any Association between Blood Groups and Lung Cancer, Independent of Histology

  • Oguz, Arzu;Unal, Dilek;Tasdemir, Arzu;Karahan, Samet;Aykas, Fatma;Mutlu, Hasan;Cihan, Yasemin Benderli;Kanbay, Mehmet
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.1
    • /
    • pp.453-456
    • /
    • 2013
  • Introduction: Lung cancer, the leading cause of cancer deaths, is divided into 2 main classes based on its biology, therapy and prognosis: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Many cases are at an advanced stage at diagnosis, which is a major obstacle to improving outcomes. It is important to define the high risk group patients for early diagnosis and chance of cure. Blood group antigens are chemical components on erythrocyte membranes but they are also expressed on a variety of epithelial cells. Links between ABO blood groups with benign or malignant diseases, such as gastric and pancreas cancers, have been observed for a long time. In this study, we aimed to investigate any possible relationship between lung cancer histological subtypes and ABO-Rh blood groups. Materials and Methods: The files of 307 pathologically confirmed lung cancer patients were reviewed retrospectively. Cases with a serologically determined blood group and Rh factor were included and those with a history of another primary cancer were excluded, leaving a total of 221. The distribution of blood groups of the lung cancer patients were compared with the distribution of blood groups of healthy donors admitted to the Turkish Red Crescent Blood Service in our city in the year 2012. Results: There was no significant difference between patients with lung cancer of either type and the control group in terms of distribution of ABO blood groups and Rh factor (p: 0.073). There was also no relationship with non small cell cancer histological subtypes. Conclusions: In this study, we found no relationship between the ABO-Rhesus blood groups and NSCLC and SCLC groups. To our knowledge this is the first analysis of ABO blood groups in SCLC patients.

Early Detection of Lung Cancer Risk Using Data Mining

  • Ahmed, Kawsar;Abdullah-Al-Emran, Abdullah-Al-Emran;Jesmin, Tasnuba;Mukti, Roushney Fatima;Rahman, Md. Zamilur;Ahmed, Farzana
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.1
    • /
    • pp.595-598
    • /
    • 2013
  • Background: Lung cancer is the leading cause of cancer death worldwide Therefore, identification of genetic as well as environmental factors is very important in developing novel methods of lung cancer prevention. However, this is a multi-layered problem. Therefore a lung cancer risk prediction system is here proposed which is easy, cost effective and time saving. Materials and Methods: Initially 400 cancer and non-cancer patients' data were collected from different diagnostic centres, pre-processed and clustered using a K-means clustering algorithm for identifying relevant and non-relevant data. Next significant frequent patterns are discovered using AprioriTid and a decision tree algorithm. Results: Finally using the significant pattern prediction tools for a lung cancer prediction system were developed. This lung cancer risk prediction system should prove helpful in detection of a person's predisposition for lung cancer. Conclusions: Most of people of Bangladesh do not even know they have lung cancer and the majority of cases are diagnosed at late stages when cure is impossible. Therefore early prediction of lung cancer should play a pivotal role in the diagnosis process and for an effective preventive strategy.

Induction of HSP27 and HSP70 by constitutive overexpression of Redd1 confers resistance of lung cancer cells to ionizing radiation

  • HYEON-OK JIN;SUNG-EUN HONG;JI-YOUNG KIM;MI-RI KIM;YOON HWAN CHANG;YOUNG JUN HONG;JIN KYUNG LEE;IN-CHUL PARK
    • Oncology Letters
    • /
    • v.41 no.5
    • /
    • pp.3119-3126
    • /
    • 2019
  • Redd1 is a stress response protein that functions as a repressor of mTORC1, a central regulator of protein translation, resulting in the inhibition of cell growth and metabolism. However, paradoxically, high Redd1 expression favors cancer progression and generates resistance to cancer therapy. Herein, we revealed that constitutive overexpression of Redd1 induced HSP27 and HSP70 expression in lung cancer cells. The expression of Redd1, HSP27 and HSP70 was highly increased in lung cancer tissues compared with that in normal lung tissues. Inhibition of HSP27 or HSP70 suppressed AKT phosphorylation, which was induced by constitutive overexpression of Redd1 and enhanced the inhibitory effects on viability of Redd1-overexpressing cells. Inhibition of AKT phosphorylation resulted in a decrease of HSP27 and HSP70 expression in Redd1-overexpressing cells. These data indicated that HSPs and AKT in Redd1-overexpressing cells positively regulated the function and expression of each other and were involved in lung cancer cell survival. Knockdown of HSP27, HSP70 or AKT enhanced ionizing radiation (IR) sensitivity, particularly in lung cancer cells in which Redd1 was stably overexpressed. Collectively, constitutive overexpression of Redd1 led to HSP27 and HSP70 induction and AKT activation, which were involved in lung cancer cell survival and resistance to IR, suggesting that Redd1 may be used as a therapeutic target for lung cancer.

Primary Lung Cancer Presenting Initially as Spontaneous Pneumothorax (폐암에 동반된 자연기흉)

  • 여승동
    • Journal of Chest Surgery
    • /
    • v.24 no.6
    • /
    • pp.631-635
    • /
    • 1991
  • Spontaneous pneumothorax is a rare manifestation of primary lung cancer and it is even more rare as an initial manifestation. Recently we have experienced three cases of lung cancer presenting initially as spontaneous pneumothorax. These three cases involved 2 men and one woman with an average age of 70 years [66 - 74years]. Lung cancer was discovered by explothoracotomy in two cases and by endoscopic biopsy in one case. In pathologic cell types, the one was alveolar cell carcinoma and the others were squamous cell carcinoma. We report these three cases of primary lung cancer presenting initially as spontaneous pneumothorax with review of the literatures.

  • PDF

Lung Cancer Found in the Patient with Thoracic Postherpetic Neuralgia -A case report- (흉부 대상포진후 신경통 환자에서 발견된 폐종양 -증례 보고-)

  • Kim, Sun-Hee
    • The Korean Journal of Pain
    • /
    • v.11 no.2
    • /
    • pp.335-337
    • /
    • 1998
  • This is a case report of a 69 years old non-smoking male patient with a lung cancer who presented with postherpetic neuralgia on the left T2, 3 and 4 dermatomes. This pain was aggravated in supine position. The patient did not have any other symtoms or signs to suggest the possibility of a lung cancer. Patient's baseline laboratory findings were essentially normal. Routine chest X-ray revealed hazy densities in the left apex. Further evaluation with chest CT confirmed the presence of a lung cancer corresponding to the densities seen on the chest X-ray.

  • PDF

A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer

  • Yang, Song
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.14
    • /
    • pp.5963-5966
    • /
    • 2015
  • Background: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabine and nedaplatin in treating patients with non-small cell lung cancer. Methods: Clinical studies evaluating the efficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety for patients with non-small cell lung cancer were identified using a predefined search strategy. Pooled response rates for gemcitabine and nedaplatin were calculated. Results: In gemcitabine and nedaplatin based regimens, 4 clinical studies including 112 patients with non-small cell lung cancer were considered eligible for inclusion. The pooled analysis suggested that the pooled reponse rate was 40.2% (45/112). Main side effects included grade 3-4 neutropenia, thrombocytopenia, and anemia. Grade 3-4 nonhematological toxicity included nausea and vomiting, diarrhea, and hepatic dysfunction. There were no treatment-related deaths. Conclusion: This evidence based analysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate and accepted toxicity for treating patients with non-small cell lung cancer.

Identification of Serial DNA Methylation Changes in the Blood Samples of Patients with Lung Cancer

  • Moon, Da Hye;Kwon, Sung Ok;Kim, Woo Jin;Hong, Yoonki
    • Tuberculosis and Respiratory Diseases
    • /
    • v.82 no.2
    • /
    • pp.126-132
    • /
    • 2019
  • Background: The development of lung cancer results from the interaction between genetic mutations and dynamic epigenetic alterations, although the exact mechanisms are not completely understood. Changes in DNA methylation may be a promising biomarker for early detection and prognosis of lung cancer. We evaluated the serial changes in genome-wide DNA methylation patterns in blood samples of lung cancer patients. Methods: Blood samples were obtained for three consecutive years from three patients (2 years before, 1 year before, and after lung cancer detection) and from three control subjects (without lung cancer). We used the MethylationEPIC BeadChip method, which covers the 850,000 bp cytosine-phosphate-guanine (CpG) site, to conduct an epigenome-wide analysis. Significant differentially methylated regions (DMRs) were identified using p-values <0.05 in a correlation test identifying serial methylation changes and serial increase or decrease in ${\beta}$ value above 0.1 for three consecutive years. Results: We found three significant CpG sites with differentially methylated ${\beta}$ values and 7,105 CpG sites with significant correlation from control patients without lung cancer. However, there were no significant DMRs. In contrast, we found 11 significant CpG sites with differentially methylated ${\beta}$ values and 10,562 CpG sites with significant correlation from patients with lung cancer. There were two significant DMRs: cg21126229 (RNF212) and cg27098574 (BCAR1). Conclusion: This study revealed DNA methylation changes that might be implicated in lung cancer development. The DNA methylation changes may be the possible candidate target regions for the early detection and prevention of lung cancer.

Lung Cancer in Malabar Cancer Center in Kerala - A Descriptive Analysis

  • Bhaskarapillai, Binukumar;Kumar, Saina Sunil;Balasubramanian, Satheesan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.9
    • /
    • pp.4639-4643
    • /
    • 2012
  • The burden of lung cancer in terms of mortality is the highest among all types of cancers globally. The present study aimed to evaluate lifestyle related habits, clinico-pathological profile and treatment details of lung cancer patients who were registered at Malabar Cancer Centre (MCC), Kerala, during the calendar year 2010. A retrospective evaluation was made from medical records to gather data from 281 registered lung cancer cases in 241 males and 40 females, with a male to female ratio of 6.03: 1. Approximately 89% of the cases were above 50 years of age. Among males about 91% of the cases were smokers and 62% of them had a chronic smoking habit. Adenocarcinomas, squamous cell carcinomas, non-small cell carcinomas and small cell cancers accounted for 10.7, 13.9, 17.0 and 5.7% respectively. Out of 281 cases around 67% were diagnosed with distant metastasis and the remainder had regional lymph node involvement. However, no statistically significant difference was observed for secondary site of tumor according to gender. As majority of the cases reported at MCC were in an advanced stage of the disease, histology of the secondary site from supraclavicular lymph nodes or liver was taken for diagnosis. Initiation of population based screening for early detection of cancer, and primary and secondary prevention strategies for reducing the prevalence of tobacco consumption are high priorities to reduce the lung cancer burden in Kerala.

Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer

  • Jung, Young Ju;Oh, In-Jae;Kim, Youndong;Jung, Jong Ha;Seok, Minkyoung;Lee, Woochang;Park, Cheol Kyu;Lim, Jung-Hwan;Kim, Young-Chul;Kim, Woo-Sung;Choi, Chang-Min
    • Journal of Korean Medical Science
    • /
    • v.33 no.53
    • /
    • pp.342.1-342.6
    • /
    • 2018
  • We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ${\geq}55years$ of age and ${\geq}30pack-years$, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. $AptoDetect^{TM}$-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.